Abstract
Background: One of the major causes of failure to achieve cure in cancer patients is the development of resistance to the drugs after an initial response. EG-011 is the first-in-class Wiskott-Aldrich syndrome protein (WASP) activator (Spriano et al, AACR 2022) with anti-tumor activity in hematological cancers (Gaudio et al, AACR 2019). Here, we assessed EG-011 in the context of cellular models of secondary resistance to FDA approved agents: marginal zone lymphoma (MZL) cell lines resistant to PI3K and BTK inhibitors and multiple myeloma (MM) cell lines resistant to proteasome inhibitors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.